NR 566 ADVANCED PHARMACOLOGY CARE OF THE FAMILY
MIDTERM REVIEW 2026/2027 | Latest Chamberlain College
Guide | Pass Guaranteed - A+ Graded
Unit 1: Pharmacokinetics & Pharmacodynamics in Family Care (12
Questions)
Q1: A 68-year-old male with heart failure, hepatic cirrhosis (Child-Pugh Class B), and
chronic kidney disease (eGFR 35 mL/min/1.73m²) is prescribed lisinopril 10 mg daily
and atorvastatin 40 mg nightly. Which pharmacokinetic consideration is most critical
when evaluating medication safety in this patient?
A. Absorption of both drugs is significantly reduced in hepatic cirrhosis, requiring
doubled doses to achieve therapeutic effect [Incorrect: ACE inhibitors and statins are
not significantly affected by absorption issues in cirrhosis; the primary concern is
altered metabolism and clearance]
B. Atorvastatin undergoes extensive hepatic metabolism via CYP3A4, and hepatic
impairment increases systemic exposure, raising risk of myopathy and hepatotoxicity;
lisinopril is renally cleared and requires dose reduction in CKD stage 3b [CORRECT]
C. Lisinopril is primarily metabolized by the liver and should be discontinued in cirrhosis,
while atorvastatin is renally cleared and requires hemodialysis dosing [Incorrect:
Lisinopril is actually renally cleared as an active drug; atorvastatin is hepatically
metabolized and does NOT require renal dose adjustment as it is not dialyzable]
,D. Both drugs are safe at standard doses regardless of organ function because they
have wide therapeutic indices [Incorrect: Neither drug has a sufficiently wide therapeutic
index to ignore organ dysfunction; both require careful monitoring and dose adjustment]
Correct Answer: B
Rationale: This question tests understanding of drug metabolism and clearance
pathways in multi-organ dysfunction. Atorvastatin is extensively metabolized by
CYP3A4 in the liver; hepatic cirrhosis (Child-Pugh B) reduces metabolic capacity,
increasing systemic exposure and risk of adverse effects (myopathy, rhabdomyolysis,
hepatotoxicity). The FDA recommends caution and lowest effective doses in active liver
disease. Lisinopril is an ACE inhibitor that is NOT metabolized but excreted unchanged
by the kidneys; in CKD stage 3b (eGFR 30-44), dose reduction or extended intervals are
recommended to prevent accumulation and hyperkalemia/renal deterioration. The
combination of reduced hepatic metabolism (atorvastatin) and reduced renal clearance
(lisinopril) creates compounded risk requiring vigilant monitoring of liver enzymes, CK,
potassium, and renal function.
Q2: A 4-year-old child weighing 18 kg requires amoxicillin for acute otitis media. The
recommended dose is 80-90 mg/kg/day divided BID. Which prescription demonstrates
correct pediatric dosing calculation?
A. Amoxicillin 400 mg/5 mL, give 1 teaspoon (5 mL) twice daily for 10 days [Incorrect:
This provides only 800 mg/day (44 mg/kg/day), substantially below recommended
dosing and likely subtherapeutic]
B. Amoxicillin 400 mg/5 mL, give 2 teaspoons (10 mL) twice daily for 10 days
[CORRECT]
,C. Amoxicillin 400 mg/5 mL, give 4 teaspoons (20 mL) twice daily for 10 days [Incorrect:
This provides 3200 mg/day (178 mg/kg/day), exceeding recommended high-dose
therapy and increasing risk of adverse effects without additional efficacy]
D. Adult dose of 875 mg twice daily, crush tablets and mix with food [Incorrect: Adult
dosing in young children violates pediatric pharmacokinetic principles; children have
higher volume of distribution, different hepatic enzyme maturity, and require
weight-based dosing]
Correct Answer: B
Rationale: Pediatric dosing requires weight-based calculations accounting for
pharmacokinetic differences. For 18 kg child at 80-90 mg/kg/day: 18 × 80 = 1440
mg/day minimum; 18 × 90 = 1620 mg/day maximum. Divided BID: 720-810 mg per
dose. Option B: 10 mL × 400 mg/5 mL = 800 mg per dose × 2 = 1600 mg/day (88.9
mg/kg/day), appropriately within high-dose range for acute otitis media in children.
High-dose amoxicillin (80-90 mg/kg/day) is recommended to overcome
penicillin-resistant Streptococcus pneumoniae. Pediatric patients have proportionally
larger extracellular fluid compartments, affecting hydrophilic drug distribution, and
hepatic enzyme systems may be immature (though amoxicillin is primarily renally
cleared). Always verify calculations: mg per mL = 400/5 = 80 mg/mL; 10 mL = 800 mg.
Q3: A 35-year-old pregnant patient (28 weeks gestation) with seizure disorder
well-controlled on phenytoin presents with breakthrough seizures. Her phenytoin level is
6 mcg/mL (therapeutic 10-20). Which pharmacokinetic change in pregnancy most likely
explains this subtherapeutic level?
A. Decreased hepatic blood flow reducing phenytoin metabolism [Incorrect: Pregnancy
actually INCREASES hepatic blood flow and cardiac output, potentially increasing
metabolism]
, B. Increased volume of distribution and increased hepatic metabolism via CYP450
enzyme induction due to hormonal changes, requiring increased phenytoin doses in
third trimester [CORRECT]
C. Decreased renal clearance of phenytoin requiring dose reduction [Incorrect:
Phenytoin is primarily hepatically metabolized, not renally cleared; renal changes in
pregnancy do not significantly affect phenytoin]
D. Increased protein binding increasing free phenytoin fraction [Incorrect: Pregnancy
DECREASES protein binding (reduced albumin, increased alpha-1-acid glycoprotein
displacement), increasing free fraction but total levels drop due to increased clearance]
Correct Answer: B
Rationale: Pregnancy induces significant pharmacokinetic changes affecting drug
therapy. Phenytoin demonstrates increased volume of distribution due to expanded
plasma volume (40-50% increase in late pregnancy) and increased hepatic metabolism
via CYP450 induction (progesterone and estrogen effects). Cardiac output increases
30-50%, enhancing hepatic perfusion. These changes often necessitate 20-100% dose
increases for hepatically metabolized antiepileptics in third trimester. Additionally,
decreased albumin (hemodilution) increases free drug fraction, but increased clearance
typically dominates, requiring monitoring of both total and free levels. The therapeutic
range for total phenytoin may need adjustment (5-12 mcg/mL considered therapeutic in
late pregnancy due to reduced protein binding). This illustrates the importance of
therapeutic drug monitoring and dose adjustment in pregnancy.
Q4: A 78-year-old female with multiple chronic conditions is prescribed metformin,
gabapentin, and ciprofloxacin. Her eGFR is 42 mL/min/1.73m². Which age-related
pharmacokinetic change most significantly impacts drug safety in this patient?
MIDTERM REVIEW 2026/2027 | Latest Chamberlain College
Guide | Pass Guaranteed - A+ Graded
Unit 1: Pharmacokinetics & Pharmacodynamics in Family Care (12
Questions)
Q1: A 68-year-old male with heart failure, hepatic cirrhosis (Child-Pugh Class B), and
chronic kidney disease (eGFR 35 mL/min/1.73m²) is prescribed lisinopril 10 mg daily
and atorvastatin 40 mg nightly. Which pharmacokinetic consideration is most critical
when evaluating medication safety in this patient?
A. Absorption of both drugs is significantly reduced in hepatic cirrhosis, requiring
doubled doses to achieve therapeutic effect [Incorrect: ACE inhibitors and statins are
not significantly affected by absorption issues in cirrhosis; the primary concern is
altered metabolism and clearance]
B. Atorvastatin undergoes extensive hepatic metabolism via CYP3A4, and hepatic
impairment increases systemic exposure, raising risk of myopathy and hepatotoxicity;
lisinopril is renally cleared and requires dose reduction in CKD stage 3b [CORRECT]
C. Lisinopril is primarily metabolized by the liver and should be discontinued in cirrhosis,
while atorvastatin is renally cleared and requires hemodialysis dosing [Incorrect:
Lisinopril is actually renally cleared as an active drug; atorvastatin is hepatically
metabolized and does NOT require renal dose adjustment as it is not dialyzable]
,D. Both drugs are safe at standard doses regardless of organ function because they
have wide therapeutic indices [Incorrect: Neither drug has a sufficiently wide therapeutic
index to ignore organ dysfunction; both require careful monitoring and dose adjustment]
Correct Answer: B
Rationale: This question tests understanding of drug metabolism and clearance
pathways in multi-organ dysfunction. Atorvastatin is extensively metabolized by
CYP3A4 in the liver; hepatic cirrhosis (Child-Pugh B) reduces metabolic capacity,
increasing systemic exposure and risk of adverse effects (myopathy, rhabdomyolysis,
hepatotoxicity). The FDA recommends caution and lowest effective doses in active liver
disease. Lisinopril is an ACE inhibitor that is NOT metabolized but excreted unchanged
by the kidneys; in CKD stage 3b (eGFR 30-44), dose reduction or extended intervals are
recommended to prevent accumulation and hyperkalemia/renal deterioration. The
combination of reduced hepatic metabolism (atorvastatin) and reduced renal clearance
(lisinopril) creates compounded risk requiring vigilant monitoring of liver enzymes, CK,
potassium, and renal function.
Q2: A 4-year-old child weighing 18 kg requires amoxicillin for acute otitis media. The
recommended dose is 80-90 mg/kg/day divided BID. Which prescription demonstrates
correct pediatric dosing calculation?
A. Amoxicillin 400 mg/5 mL, give 1 teaspoon (5 mL) twice daily for 10 days [Incorrect:
This provides only 800 mg/day (44 mg/kg/day), substantially below recommended
dosing and likely subtherapeutic]
B. Amoxicillin 400 mg/5 mL, give 2 teaspoons (10 mL) twice daily for 10 days
[CORRECT]
,C. Amoxicillin 400 mg/5 mL, give 4 teaspoons (20 mL) twice daily for 10 days [Incorrect:
This provides 3200 mg/day (178 mg/kg/day), exceeding recommended high-dose
therapy and increasing risk of adverse effects without additional efficacy]
D. Adult dose of 875 mg twice daily, crush tablets and mix with food [Incorrect: Adult
dosing in young children violates pediatric pharmacokinetic principles; children have
higher volume of distribution, different hepatic enzyme maturity, and require
weight-based dosing]
Correct Answer: B
Rationale: Pediatric dosing requires weight-based calculations accounting for
pharmacokinetic differences. For 18 kg child at 80-90 mg/kg/day: 18 × 80 = 1440
mg/day minimum; 18 × 90 = 1620 mg/day maximum. Divided BID: 720-810 mg per
dose. Option B: 10 mL × 400 mg/5 mL = 800 mg per dose × 2 = 1600 mg/day (88.9
mg/kg/day), appropriately within high-dose range for acute otitis media in children.
High-dose amoxicillin (80-90 mg/kg/day) is recommended to overcome
penicillin-resistant Streptococcus pneumoniae. Pediatric patients have proportionally
larger extracellular fluid compartments, affecting hydrophilic drug distribution, and
hepatic enzyme systems may be immature (though amoxicillin is primarily renally
cleared). Always verify calculations: mg per mL = 400/5 = 80 mg/mL; 10 mL = 800 mg.
Q3: A 35-year-old pregnant patient (28 weeks gestation) with seizure disorder
well-controlled on phenytoin presents with breakthrough seizures. Her phenytoin level is
6 mcg/mL (therapeutic 10-20). Which pharmacokinetic change in pregnancy most likely
explains this subtherapeutic level?
A. Decreased hepatic blood flow reducing phenytoin metabolism [Incorrect: Pregnancy
actually INCREASES hepatic blood flow and cardiac output, potentially increasing
metabolism]
, B. Increased volume of distribution and increased hepatic metabolism via CYP450
enzyme induction due to hormonal changes, requiring increased phenytoin doses in
third trimester [CORRECT]
C. Decreased renal clearance of phenytoin requiring dose reduction [Incorrect:
Phenytoin is primarily hepatically metabolized, not renally cleared; renal changes in
pregnancy do not significantly affect phenytoin]
D. Increased protein binding increasing free phenytoin fraction [Incorrect: Pregnancy
DECREASES protein binding (reduced albumin, increased alpha-1-acid glycoprotein
displacement), increasing free fraction but total levels drop due to increased clearance]
Correct Answer: B
Rationale: Pregnancy induces significant pharmacokinetic changes affecting drug
therapy. Phenytoin demonstrates increased volume of distribution due to expanded
plasma volume (40-50% increase in late pregnancy) and increased hepatic metabolism
via CYP450 induction (progesterone and estrogen effects). Cardiac output increases
30-50%, enhancing hepatic perfusion. These changes often necessitate 20-100% dose
increases for hepatically metabolized antiepileptics in third trimester. Additionally,
decreased albumin (hemodilution) increases free drug fraction, but increased clearance
typically dominates, requiring monitoring of both total and free levels. The therapeutic
range for total phenytoin may need adjustment (5-12 mcg/mL considered therapeutic in
late pregnancy due to reduced protein binding). This illustrates the importance of
therapeutic drug monitoring and dose adjustment in pregnancy.
Q4: A 78-year-old female with multiple chronic conditions is prescribed metformin,
gabapentin, and ciprofloxacin. Her eGFR is 42 mL/min/1.73m². Which age-related
pharmacokinetic change most significantly impacts drug safety in this patient?
